Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Viruses ; 13(12)2021 11 26.
Article in English | MEDLINE | ID: mdl-34960640

ABSTRACT

Hepatitis Delta virus (HDV) is a satellite of the Hepatitis B virus (HBV) and causes severe liver disease. The estimated prevalence of 15-20 million infected people worldwide may be underestimated as international diagnostic guidelines are not routinely followed. Possible reasons for this include the limited awareness among healthcare providers, the requirement for costly equipment and specialized training, and a lack of access to reliable tests in regions with poor medical infrastructure. In this study, we developed an HDV rapid test for the detection of antibodies against the hepatitis delta antigen (anti-HDV) in serum and plasma. The test is based on a novel recombinant large hepatitis delta antigen that can detect anti-HDV in a concentration-dependent manner with pan-genotypic activity across all known HDV genotypes. We evaluated the performance of this test on a cohort of 474 patient samples and found that it has a sensitivity of 94.6% (314/332) and a specificity of 100% (142/142) when compared to a diagnostic gold-standard ELISA. It also works robustly for a broad range of anti-HDV titers. We anticipate this novel HDV rapid test to be an important tool for epidemiological studies and clinical diagnostics, especially in regions that currently lack access to reliable HDV testing.


Subject(s)
Antibodies, Viral/blood , Hepatitis D, Chronic/diagnosis , Hepatitis D/diagnosis , Hepatitis Delta Virus/immunology , Hepatitis delta Antigens/immunology , Point-of-Care Testing , Cohort Studies , Enzyme-Linked Immunosorbent Assay , Genotype , Hepatitis D/virology , Hepatitis D, Chronic/virology , Hepatitis Delta Virus/genetics , Hepatitis Delta Virus/isolation & purification , Humans , Prevalence , Recombinant Proteins , Sensitivity and Specificity , Serologic Tests , Time Factors
2.
Viruses ; 13(9)2021 09 10.
Article in English | MEDLINE | ID: mdl-34578380

ABSTRACT

HDV infection causes severe liver disease, the global health burden of which may be underestimated due to limited epidemiological data. HDV depends on HBV for infection, but recent studies indicated that dissemination can also be supported by other helper viruses such as HCV. We used a rapid point-of-care test and an ELISA to retrospectively test for antibodies against the Hepatitis Delta antigen (anti-HDV-Ab) in 4103 HBsAg-positive and 1661 HBsAg-negative, anti-HCV-positive sera from China and Germany. We found that the HDV seroprevalence in HBsAg-positive patients in China is limited to geographic hotspots (Inner Mongolia: 35/251, 13.9%; Xinjiang: 7/180, 3.9%) and high-risk intravenous drug users (HBV mono-infected: 23/247, 9.3%; HBV-HCV co-infected: 34/107, 31.8%), while none of the 2634 HBsAg carriers from other metropolitan regions were anti-HDV-Ab-positive. In Germany, we recorded an HDV seroprevalence of 5.3% in a university hospital environment. In a cohort of HBsAg-negative, anti-HCV-positive patients that were not exposed to HBV before (anti-HBc-negative), HDV was not associated with HCV mono-infection (Chinese high-risk cohort: 0/365, 0.0%; German mixed cohort: 0/263, 0.0%). However, 21/1033 (2.0%) high-risk HCV patients in China with markers of a previously cleared HBV infection (anti-HBc-positive) were positive for anti-HDV-Ab, with two of them being positive for both HDV and HCV RNA but negative for HBV DNA. The absence of anti-HDV-Ab in HCV mono-infected patients shows that HCV cannot promote HDV transmission in humans.


Subject(s)
Hepacivirus/immunology , Hepatitis B Surface Antigens/blood , Hepatitis C Antibodies/blood , Hepatitis C/epidemiology , Hepatitis D/epidemiology , Hepatitis D/immunology , Hepatitis Delta Virus/immunology , China/epidemiology , Coinfection/epidemiology , Coinfection/virology , Germany/epidemiology , Hepatitis Antibodies/blood , Hepatitis B virus/immunology , Humans , RNA, Viral/blood , Retrospective Studies , Seroepidemiologic Studies
3.
J Biol Chem ; 295(6): 1694-1703, 2020 02 07.
Article in English | MEDLINE | ID: mdl-31914414

ABSTRACT

Small-molecule inhibitors of translation are critical tools to study the molecular mechanisms of protein synthesis. In this study, we sought to characterize how QL47, a host-targeted, small-molecule antiviral agent, inhibits steady-state viral protein expression. We demonstrate that this small molecule broadly inhibits both viral and host protein synthesis and targets a translation step specific to eukaryotic cells. We show that QL47 inhibits protein neosynthesis initiated by both canonical cap-driven and noncanonical initiation strategies, most likely by targeting an early step in translation elongation. Our findings thus establish QL47 as a new small-molecule inhibitor that can be utilized to probe the eukaryotic translation machinery and that can be further developed as a new therapeutic agent.


Subject(s)
Antiviral Agents/pharmacology , Protein Biosynthesis/drug effects , Small Molecule Libraries/pharmacology , Antiviral Agents/chemistry , Cell Line , HEK293 Cells , Humans , Proteins/metabolism , Small Molecule Libraries/chemistry , Viral Proteins/metabolism , Virus Diseases/drug therapy , Virus Diseases/metabolism , Viruses/drug effects , Viruses/metabolism
4.
J Virol ; 93(6)2019 03 15.
Article in English | MEDLINE | ID: mdl-30602609

ABSTRACT

Human norovirus infections are a major disease burden. In this study, we analyzed three new norovirus-specific Nanobodies that interacted with the prototype human norovirus (i.e., genogroup I genotype 1 [GI.1]). We showed that the Nanobodies bound on the side (Nano-7 and Nano-62) and top (Nano-94) of the capsid-protruding (P) domain using X-ray crystallography. Nano-7 and Nano-62 bound at a similar region on the P domain, but the orientations of these two Nanobodies clashed with the shell (S) domain and neighboring P domains on intact particles. This finding suggested that the P domains on the particles should shift in order for Nano-7 and Nano-62 to bind to intact particles. Interestingly, both Nano-7 and Nano-94 were capable of blocking norovirus virus-like particles (VLPs) from binding to histo-blood group antigens (HBGAs), which are important cofactors for norovirus infection. Previously, we showed that the GI.1 HBGA pocket could be blocked with the soluble human milk oligosaccharide 2-fucosyllactose (2'FL). In the current study, we showed that a combined treatment of Nano-7 or Nano-94 with 2'FL enhanced the blocking potential with an additive (Nano-7) or synergistic (Nano-94) effect. We also found that GII Nanobodies with 2'FL also enhanced inhibition. The Nanobody inhibition likely occurred by different mechanisms, including particle aggregation or particle disassembly, whereas 2'FL blocked the HBGA binding site. Overall, these new data showed that the positive effect of the addition of 2'FL was not limited to a single mode of action of Nanobodies or to a single norovirus genogroup.IMPORTANCE The discovery of vulnerable regions on norovirus particles is instrumental in the development of effective inhibitors, particularly for GI noroviruses that are genetically diverse. Analysis of these GI.1-specific Nanobodies has shown that similar to GII norovirus particles, the GI particles have vulnerable regions. The only known cofactor region, the HBGA binding pocket, represents the main target for inhibition. With a combination treatment, i.e., the addition of Nano-7 or Nano-94 with 2'FL, the effect of inhibition was increased. Therefore, combination drug treatments might offer a better approach to combat norovirus infections, especially since the GI genotypes are highly diverse and are continually changing the capsid landscape, and few conserved epitopes have so far been identified.


Subject(s)
Caliciviridae Infections/immunology , Norovirus/immunology , Single-Domain Antibodies/immunology , Binding Sites/immunology , Blood Group Antigens/immunology , Capsid/immunology , Capsid Proteins/immunology , Crystallography, X-Ray/methods , Epitopes/immunology , Escherichia coli/virology , Protein Binding/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...